Forschungsinstitut Diabetes-Akademie Mergentheim FIDAM

What Forschungsinstitut Diabetes-Akademie Mergentheim FIDAM does

FIDAM (Forschungsinstitut Diabetes-Akademie Mergentheim) is a privately held German diabetes research institute (GmbH) headquartered in Bad Mergentheim within the Diabetes Zentrum Mergentheim complex, directly affiliated with the Diabetes-Klinik Bad Mergentheim — the largest inpatient diabetes facility in Germany, treating approximately 4,000 patients annually. Founded in 2006, the institute operates with a small core team of six employees under managing directors Prof. Dr. Norbert Hermanns and Prof. Dr. Bernhard Kulzer. Its mission is to develop, evaluate, and disseminate scientifically grounded therapy and education concepts addressing both medical and psycho-social aspects of diabetes mellitus.

The core product is a portfolio of 11+ structured education and treatment programs (MEDIAS 2 BASIS/BOT+SIT+CT/ICT, PRIMAS, flash CGM/ICT, feedback CGM/BSC, HyPOS, INPUT, KetoAWARE, RenalAWARE, think) covering Type 1 and Type 2 diabetes, CGM, insulin pumps, hypoglycemia, ketoacidosis, CKD, and GLP-1 therapy. Each program is evaluated in randomized controlled trials and certified by the Deutsche Diabetes Gesellschaft (DDG) and accredited by the Bundesamt für Soziale Sicherung (BAS) for DMP reimbursement across all 17 Kassenärztliche Vereinigung regions in Germany. Supporting technology includes a proprietary EMA (Ecological Momentary Assessment) smartphone app, the dia.link online survey panel, and the annual dt-report survey on diabetes technology adoption in the DACH region. FIDAM also runs full-service CRO activities for clinical trials focused on diabetes technology (CGM, AID systems) and digital health applications (DiGAs), conducts commissioned real-world evidence studies, and provides consulting on study design, PRO validation, and human factors.

Revenue is generated via four streams: (1) fee-based HCP seminars (€325–€445 per seat, capped at 24–26 participants) booked through the FIDAM website; (2) sale of structured education materials through exclusive distributor MedTriX GmbH; (3) CRO services for pharmaceutical and medical technology companies; and (4) commissioned surveys, real-world evidence, and consulting. The institute is a human factors research partner in EU-funded consortia FORGETDIABETES and MuSiC4Diabetes, and has received an independent medical education grant from AstraZeneca for the KetoAWARE program. There are no public funding rounds, subsidiaries, or international legal entities.

Name

Forschungsinstitut Diabetes-Akademie Mergentheim FIDAM

Legal name

Forschungsinstitut Diabetes-Akademie Bad Mergentheim

Website

https://fidam.de

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

FIDAM is a German diabetes research institute that develops, certifies, and delivers DDG/BAS-accredited structured education programs, CRO services, and real-world evidence studies for healthcare professionals and pharma/medtech clients across Germany and the DACH region.

Ownership category

akta.pro rank

Product category

Diabetes Research & Medical Education Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in the Social Sciences and Humanities (541720), Marketing Research and Public Opinion Polling (54191)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Diabetes (General) (HLAKADAA)

akta.pro secondary industries

Type 1 Diabetes Care (HLAKADAB), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Diabetes research services
• Structured diabetes education
• Clinical trial services
• Medical education programs
• Real-world evidence research

Headquarters

HQ city

Bad Mergentheim

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Professional Seminars and Training: FIDAM conducts fee-based seminars (online and in-person) for healthcare professionals (doctors and diabetes counselors) to qualify them in the use of FIDAM's structured education and treatment programs. Participation is limited to 24-26 participants per seminar. Fees range from approximately €325 to €445 per seminar, with online and printed material options.
2. Training Materials Sales: Sale of structured education program materials (digital slides, manuals, patient books, worksheets, card sets, dietary games) through MedTriX GmbH distribution (www.diabetes-schulungs-lounge.de, www.mtx-shop.de) to healthcare professionals.
3. Clinical Trial Services (CRO): Full-service CRO services for clinical trials focused on diabetes technology (CGM, AID systems) and digital health solutions (DiGAs), including study design, ethics submissions, multi-site coordination across Germany, monitoring, data management, statistical analysis, and publication support.
4. Real-World Evidence and Survey Services: Commissioned surveys and research studies conducted via the dia.link panel for pharmaceutical companies, medical technology companies, researchers, and policymakers seeking feedback from people with diabetes, relatives, and healthcare providers.
5. Consulting Services: Advisory services drawing on FIDAM's extensive expertise in psycho-social and medical diabetes research, regulatory and health policy matters, study planning, human factors in diabetes technology, and patient-reported outcomes (PRO) selection.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

FIDAM develops, evaluates, and delivers certified structured diabetes education and treatment programs (MEDIAS 2, PRIMAS, HyPOS, INPUT, flash CGM/ICT, feedback CGM/BSC, KetoAWARE, RenalAWARE, think) used by healthcare professionals to train people with Type 1 and Type 2 diabetes. In parallel, it operates as a specialized Contract Research Organization (CRO) for diabetes technology and digital health clinical trials, conducts commissioned real-world evidence studies via the dia.link online panel, and provides consulting on psycho-social diabetes research, regulatory, and health policy matters.

Product overview

FIDAM (Forschungsinstitut Diabetes-Akademie Mergentheim) is a diabetes research institute offering a comprehensive portfolio of certified diabetes education and training programs. The core offerings include the MEDIAS 2 program suite (BASIS, BOT+SIT+CT, ICT) for Type 2 diabetes covering various insulin therapy approaches, and PRIMAS for Type 1 diabetes. Specialized technology-focused programs include flash CGM/ICT and feedback CGM/BSC for continuous glucose monitoring users. Condition-specific programs address hypoglycemia perception (HyPOS), insulin pump therapy (INPUT), ketoacidosis (KetoAWARE), chronic kidney disease (RenalAWARE), and GLP-1 therapy (think). FIDAM also operates dia.link, an online survey panel for real-world evidence collection, and publishes the annual dt-report on diabetes technology. Supporting infrastructure includes an EMA (Ecological Momentary Assessment) app for smartphone-based research surveys. All programs have been evaluated in randomized controlled trials and accredited by DDG (German Diabetes Association) and BAS (Federal Office for Social Security) for use in DMP (Disease Management Programs).

Differentiator

Problem solved

Functional benefit

Products and services

• MEDIAS 2 BASIS Training program for people with Type 2 diabetes not treated with insulin, covering 12 course units over 6-12 weeks with topics including disease understanding, treatment methods, lifestyle changes, and self-management skills. Used by trained healthcare professionals in DMP-billable outpatient education.
• MEDIAS 2 BOT+SIT+CT Training program for people with Type 2 diabetes and non-intensive insulin therapy (basal-supported oral therapy, supplementary therapy, or conventional therapy), consisting of 6 course units.
• MEDIAS 2 ICT Training program for people with Type 2 diabetes on intensified insulin therapy, covering 12 course units with focus on insulin therapy adjustment, carbohydrate counting, and hypoglycemia prevention.
• PRIMAS Comprehensive training program for adults with Type 1 diabetes using intensified insulin therapy or insulin pump therapy, featuring 12 content areas including glucose management, nutrition, exercise, and psychosocial aspects.
• flash CGM/ICT Training program for people with Type 1 or Type 2 diabetes using real-time continuous glucose monitoring (rtCGM) with intensified insulin therapy, consisting of 4 course units over 6 weeks.
• feedback CGM/BSC Training program for people with Type 2 diabetes on non-intensive insulin therapy (basal therapy, BOT, SIT, CT) who use continuous glucose monitoring, consisting of 4 course units.
• HyPOS Training program for people with diabetes and hypoglycemia perception problems, consisting of 5 course units focused on better perceiving, coping with, and preventing hypoglycemia.
• INPUT Training program for people treating their diabetes with an insulin pump, consisting of 12 course units over 6-12 weeks, focusing on pump usage optimization and motivation.
• KetoAWARE Training program teaching skills for prevention, recognition, and treatment of ketoacidosis, particularly for people with Type 1 diabetes including those on SGLT-inhibitor therapy.
• RenalAWARE Training program specifically designed for people with diabetes and chronic kidney disease (CKD), covering kidney function, self-management strategies, and dietary considerations.
• think Training program for GLP-1 receptor agonist (GLP-1 RA) therapy, addressing barriers, explaining therapy mechanisms, improving handling of side effects, and enhancing therapy satisfaction.
• dia.link Online Survey Panel Online survey panel connecting people with diabetes, their relatives, and healthcare professionals to participate in commissioned research surveys and improve diabetes care. Used by pharmaceutical, medtech, research, and policy clients.
• dt-report Annual Survey Annual survey on diabetes technology status in Germany, Austria, Switzerland (DACH region), providing insights on technology usage, benefits, barriers, and future expectations.
• FIDAM CRO (Clinical Trial) Services Full-service CRO services for clinical trials focused on diabetes technology and digital health solutions, including study design, ethics submissions, multi-site coordination, monitoring, data management, statistical analysis, and publication support, delivered to pharmaceutical and medical technology companies.
• FIDAM Diabetes Consulting Advisory services drawing on FIDAM's expertise in psycho-social and medical diabetes research, regulatory and health policy matters, study planning, human factors in diabetes technology, and patient-reported outcomes (PRO) selection for pharmaceutical, medtech, and research clients.

Quantifiable outcome

• flash CGM/ICT program led to clinically meaningful HbA1c improvement of -0.28% in a randomized controlled trial; also improved time-in-range, reduced diabetes distress, and increased patient satisfaction with rtCGM.
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and major.

• MedTriX GmbHcoreChannel Partner/ Reseller/ DistributorMedTriX GmbH (Wiesbaden) serves as the exclusive distributor for all FIDAM structured education program materials (digital slides, manuals, patient books, worksheets) through www.diabetes-schulungs-lounge.de and www.mtx-shop.de. FIDAM also exhibits at the MedTriX Group booth at the DDG Diabeteskongress.
• Diabetes-Klinik Bad MergentheimcoreStrategic or Co-development PartnerFIDAM is integrated into the Diabetes Zentrum Mergentheim along with the Diabetes-Klinik Bad Mergentheim. With approximately 4,000 patients annually, the clinic is the largest inpatient diabetes facility in Germany and serves as FIDAM's clinical study recruitment center.
• EU Research ConsortiamajorStrategic or Co-development PartnerFIDAM serves as the human factors research partner in two EU-funded projects: FORGETDIABETES (forgetdiabetes.eu) and MuSiC4Diabetes (music4diabetes.eu), both focused on the development of fully implantable AID (automated insulin delivery) systems enabling fully closed-loop insulin dosing.
• Deutsche Diabetes Gesellschaft (DDG)coreStrategic or Co-development PartnerDDG is the German Diabetes Association that certifies FIDAM's structured education and treatment programs. FIDAM regularly participates in DDG's annual Diabeteskongress with presentations and exhibitions. DDG certification is a prerequisite for BAS accreditation and DMP billing.
• Bundesamt für Soziale Sicherung (BAS)coreStrategic or Co-development PartnerBAS (Federal Office for Social Security) reviews and approves FIDAM's structured education programs for inclusion in Germany's Disease Management Programmes (DMP) for Type 1 and Type 2 diabetes, enabling healthcare professionals to bill FIDAM's programs through statutory health insurance.
• Kassenärztliche Vereinigung (KV) RegionscoreChannel Partner/ Reseller/ DistributorFIDAM's programs are listed in contracts with statutory health insurers across all 17 KV regions in Germany, enabling trained healthcare professionals to bill for FIDAM program delivery through regional KV reimbursement agreements.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Diabetes UK: UK diabetes charity providing patient education, professional training, and research funding. Comparable to FIDAM's HCP training and patient-education programs in scope, though serving the UK NHS pathway rather than the German DMP system.

Emerging players

• mySugr (Roche Diabetes Care): Digital diabetes self-management platform with a strong DACH presence and DiGA reimbursement in Germany. Compares to FIDAM's digital training and chatbot capabilities on the patient-engagement side, though mySugr is consumer-facing rather than HCP-training.

Others

• JDRF (Breakthrough T1D): Global Type 1 diabetes research funding and advocacy organization. Comparable to FIDAM in driving T1D research priorities and funding clinical studies, but as a funder/convener rather than a CRO or education provider.
• MedTriX GmbH: Diabetes communications and education services company that is currently FIDAM's exclusive distribution partner for program materials. Listed as an OTHERS peer because of its channel/administrative relationship to FIDAM rather than direct product competition.

Direct peers

• dQ&A – The Diabetes Research Company: US-based diabetes market research firm running large-scale patient and HCP panels and annual diabetes technology reports. Directly comparable to FIDAM's dia.link panel and dt-report methodology.
• Diabetes Center Berne: Swiss diabetes research and technology center focused on closed-loop systems, CGM, and digital diabetes tools. Comparable to FIDAM in combining clinical research, education, and consortia work on next-generation AID technology.
• Profil Institut für Stoffwechselforschung: German CRO specializing in metabolic disease clinical trials, including diabetes technology and obesity. Closest direct competitor to FIDAM's CRO services with a similar academic-research heritage and pharma/MedTech customer base.
• Institut für Diabetesforschung und Metabolische Erkrankungen (IDM) Helmholtz Munich: German academic diabetes research institute at Helmholtz Munich studying Type 1/Type 2 diabetes pathophysiology and prevention. Overlaps with FIDAM in psycho-social and clinical diabetes research, and serves a similar academic/pharma stakeholder base.

Broad incumbents

• IQVIA: Global full-service CRO and real-world evidence provider with extensive diabetes and MedTech trial experience. Relevant as a scaled competitor for FIDAM's CRO and RWE work, though lacking FIDAM's psycho-social specialization and German DMP education footprint.
• RTI International: Large nonprofit research institute offering commercial clinical, survey, and real-world evidence services. Overlaps with FIDAM's commissioned RWE/survey work and CRO capabilities, though at a much larger scale and without FIDAM's diabetes specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/fidam-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Forschungsinstitut Diabetes-Akademie Mergentheim FIDAM